{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thyroid+Carcinoma%2C+Anaplastic&page=2", "query": { "condition": "Thyroid Carcinoma, Anaplastic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thyroid+Carcinoma%2C+Anaplastic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:17:59.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004089", "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "15 Years to 80 Years" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 3, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004089" }, { "nct_id": "NCT04418167", "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "JSI-1187", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "JS InnoPharm, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2020-06-18", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04418167" }, { "nct_id": "NCT02404441", "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Sell Lung Cancer (NSCLC)", "Triple Negative Breast Cancer", "Anaplastic Thyroid Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 319, "start_date": "2015-04-27", "completion_date": "2020-07-21", "has_results": true, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02404441" }, { "nct_id": "NCT06007924", "title": "A Study of Avutometinib and Defactinib in People With Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Avutometinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-08-16", "completion_date": "2027-08-16", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007924" }, { "nct_id": "NCT05059470", "title": "IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-02-11", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059470" }, { "nct_id": "NCT05453799", "title": "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma" ], "interventions": [ { "name": "Vudalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2022-07-21", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453799" }, { "nct_id": "NCT06902376", "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Thyroid Cancer", "Thyroid Cancer", "BRAF Mutation-Related Tumors" ], "interventions": [ { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "XL092", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-06-03", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06902376" }, { "nct_id": "NCT03449108", "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Sarcoma", "Dedifferentiated Chondrosarcoma", "Giant Cell Tumor of Bone", "Malignancy in Giant Cell Tumor of Bone", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Platinum-Resistant Ovarian Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Osteosarcoma", "Recurrent Ovarian Carcinoma", "Refractory Osteosarcoma", "Soft Tissue Sarcoma", "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Squamous Cell Carcinoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2018-04-27", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449108" }, { "nct_id": "NCT00654238", "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Differentiated Thyroid Cancer", "Metastatic Poorly Differentiated Thyroid Cancer", "Metastatic Anaplastic Thyroid Cancer", "Metastatic Medullary Thyroid Cancer" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2006-02", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654238" }, { "nct_id": "NCT04171622", "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8", "Thyroid Gland Squamous Cell Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-11-04", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-11T04:17:59.533Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04171622" } ] }